Received May 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | OT |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | — | OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | OT |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | OT |
No adverse event; Inbound call from HCP stating that a 2nd dose of MMR-II and VARIVAX were inadvertently administered before the recommended age. These vaccines were administered at 2 years old. The first dose of both of these vaccines were administered on May 3rd, 20; This spontaneous report was received from a consumer or other non health professional and refers to a) 2-year-old patient of unknown gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 03-MAY-2024, the patient was vaccinated with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), 0.5 mL administered by unknown route (anatomical location, lot # and expiration date were not reported) and with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), 0.5 mL administered by unknown route as prophylaxis (anatomical location, lot # and expiration date were not reported). The suspect vaccine were reconstituted with sterile diluent (lot # and expiration date were not reported). Then on 17-APR-2025 at 2 year of age, the patient was vaccinated with the second dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (as described above) and with the second of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) (as described above), inadvertently administered before the recommended age (inappropriate age at vaccine administration). Patient had not experienced any reactions (no adverse event). Lot # is being requested and will be submitted if received
Diluent Mrk